
Novocure (NVCR) Stock Forecast & Price Target
Novocure (NVCR) Analyst Ratings
Bulls say
NovoCure Ltd has demonstrated positive financial momentum with a reported 4Q25 revenue of $174.4 million, reflecting a 4% sequential increase and an 8% year-over-year improvement, contributing to a full-year revenue of $655.4 million for 2025. The company has seen an 8% growth in Optune Lua prescriptions for Non-small cell lung cancer, bolstered by national reimbursement in Spain, which is anticipated to further enhance revenue in 2026. Overall, continued growth in the U.S. market, supported by robust sales dynamics and ongoing clinical trials, augurs well for NovoCure’s financial future.
Bears say
NovoCure Ltd faces a negative outlook primarily due to a decrease in revenue estimates, with projections for Glioblastoma revenue reduced from $702 million to $690 million and total revenue revised down from $738.9 million to $711.3 million for 2026. Challenges in market adoption and commercialization efforts for its products, particularly the Optune line, have led to concerns about subpar sales performance and potential clinical failures across various indications. Additionally, several risks, including safety issues, efficacy concerns, increased competition, and regulatory uncertainties, further contribute to the company's precarious financial trajectory.
This aggregate rating is based on analysts' research of Novocure and is not a guaranteed prediction by Public.com or investment advice.
Novocure (NVCR) Analyst Forecast & Price Prediction
Start investing in Novocure (NVCR)
Order type
Buy in
Order amount
Est. shares
0 shares